Personal information

No personal information available

Activities

Collapse all

Works (5)

HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases

Journal of Internal Medicine
2023-05 | Journal article
DOI: 10.1111/joim.13616
Contributors: Marthe Kirkesæther Brun; Kristin Hammersbøen Bjørlykke; Marte K. Viken; Grethe‐Elisabeth Stenvik; Rolf A. Klaasen; Johanna E. Gehin; David John Warren; Joseph Sexton; Øystein Sandanger; Tore K. Kvien et al.
Source: check_circle
Crossref

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

BioDrugs
2022-11 | Journal article
DOI: 10.1007/s40259-022-00559-1
Contributors: Johanna Elin Gehin; Guro Løvik Goll; Marthe Kirkesæther Brun; Meghna Jani; Nils Bolstad; Silje Watterdal Syversen
Source: check_circle
Crossref

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

Journal of Internal Medicine
2022-09 | Journal article
DOI: 10.1111/joim.13495
Contributors: Marthe Kirkesæther Brun; Guro Løvik Goll; Kristin Kaasen Jørgensen; Joseph Sexton; Johanna Elin Gehin; Øystein Sandanger; Inge Christoffer Olsen; Rolf Anton Klaasen; David John Warren; Cato Mørk et al.
Source: check_circle
Crossref

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

JAMA
2021-12 | Journal article
DOI: 10.1001/jama.2021.21316
PMID: 34932077
PMC: PMC8693274
Contributors: Syversen SW; Jørgensen KK; Goll GL; Brun MK; Sandanger Ø; Bjørlykke KH; Sexton J; Olsen IC; Gehin JE; Warren DJ et al.
Source: Self-asserted source
Marthe Brun via Europe PubMed Central

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

JAMA
2021-05 | Journal article
DOI: 10.1001/jama.2021.4172
PMID: 33944876
PMC: PMC8097498
Contributors: Syversen SW; Goll GL; Jørgensen KK; Sandanger Ø; Sexton J; Olsen IC; Gehin JE; Warren DJ; Brun MK; Klaasen RA et al.
Source: Self-asserted source
Marthe Brun via Europe PubMed Central

Peer review (3 reviews for 2 publications/grants)

Review activity for Annals of the rheumatic diseases (2)
Review activity for Drugs (1)
How many people are using ORCID?